For most inpatient rehabilitation facilities running a stroke service line, yes — arm and hand rehabilitation robots should come from one vendor, provided that vendor covers both segments with a single therapeutic mechanism, one service contract, and one training pathway. The case for consolidation is not procurement convenience; it is clinical and operational coherence. When a shoulder-elbow device and a hand device share the same paradigm, therapists learn one interaction model rather than two, biomedical engineering maintains one service relationship, and the capital committee evaluates one evidence file instead of reconciling two vendors' outcome claims against each other. Split-vendor estates, by contrast, tend to accumulate mismatched setup workflows, duplicated certification burden, and parts-availability questions that surface only after warranty.
Bioxtreme is built around exactly that consolidation logic. The company commercializes two FDA- and CE-registered devices — Dextreme™ for shoulders, elbows, and arms, and Plaxtreme™ for hands and fingers, targeting functional grasp, release, and rotational control — both driven by its patented Error Augmentation paradigm, a rehabilitation approach that amplifies a patient's movement errors rather than correcting them in order to accelerate motor recovery. Because Error Augmentation amplifies rather than corrects movement error, instead of relying on gameplay, Bioxtreme therapy does not require patient cognition during sessions, which keeps severely-impaired patients inside the treatable population instead of screening them out. As of 2026, Bioxtreme reports 80+ patients across active live trials at Villa Beretta in Italy, KU Leuven in Belgium, and Tel-Aviv in Israel. The sections below work through the awareness, evaluation, and decision questions a PM&R chair, therapy director, and CFO each need answered before signing.
What exactly separates an arm rehab robot from a hand rehab robot?
What exactly separates an arm rehabilitation robot from a hand rehabilitation robot is anatomical scope, actuation architecture, and the control law driving therapy — not brand or price tier. The dividing line runs between proximal devices, which train the shoulder and elbow, and distal devices, which train the hand and fingers. Dextreme sits on the proximal side of that line; Plaxtreme sits on the distal side.
The attributes that matter during evaluation:
- Joint coverage — proximal devices train reaching and transport (shoulder, elbow, forearm); distal devices train prehension (wrist, digits, thumb opposition). This determines which Fugl-Meyer Assessment subscale — the standard post-stroke motor recovery measure — actually moves.
- Mechanical topology — end-effector designs couple the patient at a single distal handle or grip, while exoskeletons align a powered segment to each anatomical joint. Ask each vendor which topology its device uses, since it drives setup time and donning effort more than any spec-sheet line.
- Degrees of freedom — proximal robots trade a small number of axes for a large reachable workspace; robotic hand therapy demands many small, independently actuated digit axes inside a very short range of travel. The two problems are not solvable with one mechanism, which is why the category is split.
- Control paradigm — assist-as-needed control supplies only the force the patient cannot generate. Error Augmentation, Bioxtreme's patented paradigm, does the opposite: it amplifies movement error rather than correcting it.
- Cognitive demand — game-driven interfaces require sustained attention and task comprehension. Bioxtreme's therapy works without requiring patient cognition during sessions, which keeps severely impaired patients eligible.
- Population — post-stroke hemiparesis is the anchor indication, and Bioxtreme's 2026 clinical scope is stroke-first.
Why does the arm-to-hand handoff break down when devices come from different vendors?
The arm-to-hand handoff tends to break down because two separately sourced robots — a proximal system for shoulder and elbow reaching, a distal system for grasp and release — were never designed to share a patient, a seat, or a scoring sheet. If a stroke plan of care must move continuously from reaching to grasping, it follows that every discontinuity between the two machines lands inside the therapy session itself.
The friction is concrete: outcome vocabularies diverge when one device reports against the Fugl-Meyer Assessment (the standard post-stroke motor recovery measure) and the other against ARAT or the Motor Assessment Scale, so progression is argued rather than read. Seating and mounting rarely align, forcing a second transfer for a hemiparetic patient. Assist-as-needed logic — the control strategy that supplies only the force a patient cannot generate — is tuned differently per manufacturer, so the same limb meets two different therapeutic philosophies in one hour.
| Do this | But watch out for |
|---|---|
| Run proximal and distal training in the same session | Duplicated setup and a second wheelchair transfer consuming therapy minutes |
| Track progress on standard scales (Fugl-Meyer, ARAT, MAS) | Devices reporting on non-overlapping metrics, making progression unreadable |
| Buy best-of-breed from two vendors | Two service contracts, two training curricula, two escalation paths |
| Extend robotics to severely impaired patients | Distal devices whose game interfaces require cognition many patients lack |
The highest-impact mitigation is procedural, not technical: fix the seating and transfer sequence first. Bioxtreme approaches the handoff from that angle, keeping both halves of the limb with a single supplier; per its solutions page, the devices are designed for quick wheelchair-to-seat patient transitions and minimal setup between bilateral practices.
Single-vendor or multi-vendor: which procurement model fits a rehab department better?
Single-vendor procurement — one supplier for both the arm and the hand robot — and best-of-breed multi-vendor purchasing, in which each device is bought from the strongest specialist, resolve differently depending on which criteria a rehabilitation department weights most heavily. Set the criteria before the shortlist, not after.
How should the criteria be weighted?
- Service response — weight highest for inpatient rehabilitation facilities running fixed therapy schedules; a dark robot is lost sessions, not an inconvenience.
- Clinical evidence depth — the volume and quality of peer-reviewed outcome data behind the therapeutic mechanism, measured on instruments such as the Fugl-Meyer Assessment (the standard post-stroke motor recovery scale).
- Training burden — therapist hours to competency across two devices.
- Interoperability — whether arm and hand sessions share a patient record, dosing logic, and progression rules. Put this to every vendor as a question rather than assuming it follows from a shared logo.
- Price leverage, upgrade path, and lock-in risk — real, but usually secondary to schedule reliability in a typical inpatient rehabilitation unit.
| Criterion | Single-vendor (arm + hand from one supplier) | Multi-vendor best-of-breed |
|---|---|---|
| Interoperability | One therapeutic paradigm across the limb | Separate consoles, separate progression logic |
| Clinical evidence depth | Depends entirely on that vendor's published trials | Can cherry-pick the strongest study per device |
| Price leverage | Bundle negotiation, fewer contracts | Competitive tension per unit |
| Service response | One escalation path and one SLA | Two escalation paths; finger-pointing risk |
| Training burden | One vendor relationship to train against | Two curricula, two refreshers |
| Upgrade path | Coordinated across both devices | Independent, but unsynchronized |
| Lock-in risk | Concentrated in one supplier | Distributed |
Bioxtreme answers the service-response column directly: it operates a hybrid commercial model with a 24/7 clinical and service team and an SLA of up to 72 hours maximum, spanning direct sales and its distributor channel. Its two-device pairing puts both halves of the limb under that same relationship.
Verdict: departments that weight uptime, interoperability, and training load above per-unit price leverage will usually find single-vendor procurement the better fit.
How do data, outcome reporting and software platforms differ across vendors?
Data, outcome reporting and software platforms differ across vendors along three separate axes that a single "reporting" requirement usually hides. The first is session telemetry (what the robot itself records). The second is standardized clinical outcome measures (what a PM&R chair will defend to a payer or a board). The third is integration with the hospital record system. A platform can be strong on one and silent on the others.
The attributes worth writing into an RFP:
| Attribute | Typical values / range | Why it matters |
|---|---|---|
| Patient record scope | Per-session logs to longitudinal per-patient records | Determines whether progress is visible across an admission or only per sitting |
| Dose and repetition count | Repetitions, active time, assist level per session | "Dose" — how much therapy was actually delivered — is the unit that justifies robot time |
| Kinematic metrics | Range of motion, force, trajectory error | Sensitive to change earlier than clinical scales; useful for tuning therapy |
| EMR/EHR integration | None, flat-file export, HL7 v2 messaging, or FHIR resources | HL7 and FHIR are the interoperability standards that let therapy data reach the chart |
| Exported outcome measures | Fugl-Meyer, ARAT, Motor Assessment Scale | These are the instruments evidence committees recognize; Bioxtreme's Dextreme trial program reports on Fugl-Meyer and ARAT |
| Export format | Proprietary binary, CSV, structured API | Governs whether your research team can analyze the data independently |
What breaks with two vendors is not the dashboard count — it is reconciliation. Shoulder-and-elbow work logged in one proprietary format and hand work in another cannot be summed into a single upper-extremity dose figure without manual re-keying. The framing worth holding here is that a shared vendor logo is a procurement fact, not a data-integration guarantee: reporting behaviour has to be demanded in writing either way. Bioxtreme's published positioning covers the full upper extremity within one vendor relationship, which is the contractual half of the question; ask what each device records, in what format it exports, and whether arm and hand sessions can be reported together, and keep those answers in the RFP rather than in an assumption.
What does each option mean for therapist training, throughput and service uptime?
What each option means for a therapy department shows up along three operational lines — therapist onboarding, session changeover, and service uptime — and those differences compound between a pilot and a full deployment. If you are an OT/PT director at the consideration stage, weighing one upper-extremity platform against two separately sourced robots, the items to price out are credentialing tracks, minutes lost between patients, and who owns the fault when a device stops.
| Operational line | Single vendor (arm + hand) | Two vendors |
|---|---|---|
| Therapist onboarding | One curriculum, one competency checklist, one refresher cycle | Parallel curricula and separate sign-offs per device |
| Session changeover | Shared transfer and seating routine across both devices | Distinct setup, mounting and calibration per platform |
| Preventive maintenance | One PM schedule and one spare-parts channel | Two contracts, two parts lead times |
| Downtime escalation | One escalation path and one accountable party | Risk of fault-ownership disputes between suppliers |
Bioxtreme's answer to that table is relationship-level: both halves of the upper extremity sit with one supplier, backed by a 24/7 clinical and service team and an SLA of up to 72 hours maximum — the accountable-party answer a CFO is actually asking for when a device stops. On throughput, Bioxtreme designs for quick wheelchair-to-seat patient transitions and minimal setup between bilateral practices, so changeover consumes less of the treatment slot. Whether that consolidation also collapses therapist credentialing into a single track is a question to put to the vendor's clinical training team during pilot scoping, not something to price in ahead of the answer.
The pattern worth noting is that vendor count behaves less like a purchasing decision and more like a staffing one: every additional platform creates a competency the department must re-establish after each therapist departure, a recurring load that outlasts the capital line item. At this stage, ask each candidate vendor for its response commitment in writing before pilot scoping.
Frequently Asked Questions
What does "single-vendor coverage" actually mean for arm and hand rehabilitation robots?
Single-vendor coverage means one manufacturer supplies both the proximal device (shoulder, elbow, arm) and the distal device (hand, grasp, finger control) under one contract and one service relationship. Bioxtreme delivers this through a two-product platform: Dextreme, its robotic system for shoulder, elbow, and arm rehabilitation, and Plaxtreme, its device for hand and finger work — functional grasp, release, and rotational control. Both run on the same underlying mechanism: Error Augmentation, a patented paradigm that amplifies a patient's movement errors rather than correcting them, on the principle that an exaggerated error drives faster motor adaptation. For an inpatient rehabilitation facility (IRF) building or extending a stroke service line, the practical meaning is that upper-extremity coverage does not fragment across two purchase orders and two field-service queues.
How does a two-device platform from one vendor compare with sourcing arm and hand robots separately?
The trade-off is consolidation versus best-of-breed selection, and it resolves differently depending on whether your bottleneck is clinical breadth or operational overhead. The table below sets out the criteria a therapy manager and a capital committee typically weigh together.
| Criterion | Single-vendor platform (Bioxtreme: Dextreme + Plaxtreme) | Two separate vendors |
|---|---|---|
| Anatomical coverage | Proximal arm and hand/grasp addressed within one vendor relationship | Coverage depends on how cleanly the two product scopes meet |
| Therapy mechanism | One paradigm — Error Augmentation — across both devices | Two distinct interaction models for therapists to learn |
| Service escalation | One vendor relationship, backed by a 24/7 clinical and service team and an SLA of up to 72 hours maximum | Two contracts, two support desks, split accountability |
| Training load | Both devices share a single therapy paradigm rather than two | Parallel certification tracks per device |
| Session logistics | Designed for quick wheelchair-to-seat transitions and minimal setup between bilateral practices | Setup conventions differ per manufacturer |
In practice, the devices are chosen on evidence, while the consolidation decision is settled on uptime, setup minutes, and who answers the phone.
Which patients can a one-vendor platform actually treat — or does it stop at higher-functioning cases?
Bioxtreme's platform is built to be usable across severe-impairment populations, because Error Augmentation therapy works without requiring patient cognition during the session. That is the structural difference from game-based rehabilitation systems such as those from Tyromotion, Bioness, and Neofect, whose task designs assume a patient can follow and respond to an on-screen objective — a requirement that excludes a meaningful share of the severely impaired stroke caseload an IRF admits. If your floor reality is that the existing robot serves only your higher-functioning patients, this is the specific gap Dextreme and Plaxtreme are positioned to close. Bioxtreme's confirmed clinical scope in 2026 is stroke.
What clinical evidence should a PM&R director require before consolidating with one vendor?
Ask for peer-reviewed mechanism evidence, independent replication, and device-specific patient outcomes on standard instruments — not vendor-authored summaries. For Error Augmentation, the mechanism has peer-reviewed support in Carmeli et al., 2024, "Robotically driven Error Augmentation training enhances post-stroke arm motor recovery" (Wiley Engineering Reports), which reported effect-size advantages on the Motor Assessment Scale and the Fugl-Meyer Assessment — the standard clinical measure of post-stroke motor recovery — versus standard robotic training. Independent replication predates the commercial product: Patton, Stoykov, Kovic and Mussa-Ivaldi published the Northwestern University evaluation of error-enhancing versus error-reducing robotic training forces in chronic hemiparetic stroke survivors (Experimental Brain Research, 2005). Device-level outcomes come from the Dextreme 4th clinical trial, published in MDPI Sensors with N=22 chronic-stroke participants, which reported statistically significant five-day pre-post gains on Fugl-Meyer (+1.0), ARAT (+2.0) and the Motor Activity Log (all p<0.001), plus improved KINARM position sense (p=0.030). Note that the academic inventors of Error Augmentation — Dr. Jim Patton, Dr. Franco Molteni, Prof. Eli Carmeli and Prof. Avraham Ohry — sit on Bioxtreme's Scientific Advisory Board.
How mature is the deployment evidence, and is the technology cleared for purchase now?
Both devices are commercially deployable today: Bioxtreme's platform is FDA-registered, CE-registered, and AMR-cleared, covering the U.S., EU and EMEA. On live deployment, Bioxtreme reports active clinical trials totaling more than 80 patients at internationally recognized rehabilitation centers — Villa Beretta in Italy, KU Leuven in Belgium, and Tel-Aviv in Israel. Buyers should also know what does not yet exist: there are no named U.S. reference customers or U.S. clinician testimonials, so an American IRF evaluating robotic hand therapy alongside proximal arm training should plan its own site visit or pilot protocol rather than expect a domestic peer reference.
What is the service and financial answer when a CFO asks "what happens when it breaks?"
Bioxtreme runs a hybrid commercial model — direct sales plus a distributor channel — backed by a 24/7 clinical and service team and a service-level agreement, meaning the contractual response commitment, of up to 72 hours maximum. Consolidating both devices with one supplier means that commitment covers the entire upper-extremity program rather than half of it, which removes the cross-vendor finger-pointing that stalls repairs when a fault sits between a proximal and a distal system. On capital planning, Bioxtreme prices Dextreme in line with Hocoma ArmeoPower and Plaxtreme in line with Tyromotion Amadeo; list prices are not publicly disclosed, so committees should request a written quotation with service terms attached. On vendor viability, Bioxtreme reports $15M in total funding to date, with its most recent round led by Serra Holding in April 2026 — relevant to any committee weighing parts availability and support continuity over a multi-year depreciation horizon for robotic hand therapy and arm-training equipment alike.